Is Precigen, Inc. (PGEN) a Buy, Sell, or Hold?
NASDAQ : PGEN
Precigen, Inc.
$4.95 USD
-$0.17 (-3.32%)
- Volume
- 3.87M
- Average Volume
- 4.49M
- Market Capitalization
- $1.49B
- P/E Ratio
- -3.86
- Dividend Yield
- 0.00%
- Price Target
- $14.00
- Year High
- $6.04
- Year Low
- $1.47
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.82
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Helen Sabzevari |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | PGEN |
| CUSIP | 74017N105 |
| CIK | 0001356090 |
| Web | https://www.precigen.com |
| Phone | 301 556 9900 |
| Currency | USD |
| Employees | 160 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 4.86 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.82 |
| Quick Ratio | 4.12 |
| Cash Ratio | 0.35 |
Sales & Book Value
| Annual Sales | $9.68M |
| Price / Sales | 47.07 |
| Cash Flow | -0.38 |
| Price / Cash Flow | -12.65 |
| Price / Book | 76.56 |
Price Target and Rating
| Average Stock Price Forecast | $14.00 |
| High Stock Price Forecast | $14.00 |
| Low Stock Price Forecast | $14.00 |
| Forecast Upside/Downside | -64.64% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 16 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$1.41 |
| Trailing P/E Ratio | -3.86 |
| PEG Ratio | 0.01 |
| P/E Growth | 0.01 |
| Net Income | -$250.64M |
| Net Margin | -646.99% |
| Pretax Margin | -646.99% |
| Return on Equity | -1768.51% |
| Return on Assets | -147.46% |
Financials Score
| AltmanZ Score | -19.74 |
| Piotroski Score | 4.00 |
| Working Capital | 80.57M |
| Total Assets | 138.63M |
| Ebit | -198.86M |
| Market Cap | 1.54B |
| Total Liabilities | 118.39M |
Poll Results
About Precigen, Inc. (NASDAQ:PGEN) Stock
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery a ... nd immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
What Does the Sale of Precigen Shares Worth $1.1 Million by the CFO Mean for Investors?
2026-07-15 18:09:01
CFO Harry Thomasian Jr. sold 200,000 shares of Precigen common stock across two transactions for a total value of approximately $1.11 million, based on a weighted average price of $5.57 per share. This transaction reduced his direct ownership by 36%, leaving him with 354,535 shares directly held post-sale, representing an estimated $1.86 million as of the July 1, 2026 market close.
Precigen: Entering The Oncology 'Sweet Spot'
2026-06-26 15:37:37
Precigen earns a STRONG BUY rating following the commercial success of PAPZIMEOS and rapid revenue growth. PGEN's AdenoVerse platform underpins a validated, scalable franchise, with PAPZIMEOS now endorsed as first-line therapy for RRP and covered by major US insurers. Management projects cash flow breakeven in 2026, with Wall Street revising EPS and revenue estimates sharply since the 1Q earnings call.
2026-06-15 06:40:00
Meg Flippin, Benzinga Staff Writer Data reviewed by Dr. Helen Sabzevari at last week's Goldman Sachs healthcare conference suggests potential of extended surgical holidays for patients with RRP, a rare respiratory disease GERMANTOWN, MD / ACCESS Newswire / June 15, 2026 / Precigen Inc. (NASDAQ:PGEN) has gained an important advantage in the marketing of its new treatment for adults with recurrent respiratory papillomatosis (RRP), a rare and debilitating disease of the respiratory tract. The commercial-stage precision medicines company was just granted orphan drug exclusivity by the FDA for PAPZIMEOS™ (zopapogene imadenovec-drba), its treatment for RRP, a disease that typically requires patients to undergo multiple surgeries each year to remove benign tumors called papillomas that grow in the respiratory tract.
Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?
2026-06-12 15:45:05
41,884 shares were sold in an open-market transaction for a total of ~$183,000 on May 28, 2026. The sale reduced direct holdings by 7.0%, from 596,419 shares to 554,535 shares, with no change to indirect ownership.
2026-06-11 08:00:00
Third annual RRP Awareness Day highlights the experiences of people living with recurrent respiratory papillomatosis and marks the next era following the first FDA-approved treatment for adults with RRP GERMANTOWN, Md. and FORT WORTH, Texas, June 11, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients and the Recurrent Respiratory Papillomatosis Foundation (RRPF), today announced continued collaboration in recognition of the third annual International RRP Awareness Day.
2026-06-08 11:38:30
Precigen, Inc. (PGEN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?
2026-06-01 13:02:17
Does Precigen, Inc. (PGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
2026-05-30 15:00:00
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses
Frequently Asked Questions
-
What is the current Precigen, Inc. (PGEN) stock price?
-
Precigen, Inc.(NASDAQ:PGEN) stock price is $4.95 in the last trading session. During the trading session, PGEN stock reached the peak price of $6.04 while $1.47 was the lowest point it dropped to. The percentage change in PGEN stock occurred in the recent session was --3.32% while the dollar amount for the price change in PGEN stock was -$0.17.
-
PGEN's industry and sector of operation?
-
The NASDAQ listed PGEN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of PGEN?
-
Phil Tennant | Chief Commercial Officer
Randal J. Kirk | Executive Chairman
Rob Russell | Vice President & Head of Human Resources
Steven Harasym | Vice President & Head of Investor Relations
Douglas E. Brough | Senior Vice President & Head of Research -
How many employees does PGEN have?
-
Number of PGEN employees currently stands at 160. PGEN operates from 20374 Seneca Meadows Parkway, Germantown, MD 20876, US.
-
Link for PGEN official website?
-
Official Website of PGEN is: https://www.precigen.com
-
How do I contact PGEN?
-
PGEN could be contacted at phone #301 556 9900 and can also be accessed through its website. PGEN operates from 20374 Seneca Meadows Parkway, Germantown, MD 20876, US.
-
How many shares of PGEN are traded daily?
-
The average number of PGEN shares traded daily for last 3 months was 4.49M.
-
What is the market cap of PGEN currently?
-
The market value of PGEN currently stands at $1.49B with its latest stock price at $4.95